Abstract：Objective To investigate effect of third-line therapy of Apatinib combined with Capecitabine on the advanced triple negative breast cancer (TNBC). Methods A total of 78 patients with advanced TNBC who failed secondline chemotherapy in Anshan Cancer Hospital from May 2018 to May 2019 were selected and randomly divided into study group and reference group, with 39 cases in each group. The reference group was treated with Capecitabine monotherapy for three-line treatment, and the study group was treated with Apatinib combined with Capecitabine for three-line treatment. The clinical efficacy of the two groups of TNBC patients after treatment was compared, including the objective response rate (ORR)and disease control rate (DCR),the survival rate of the two groups of patients within 1 year after treatment was followed up, and the occurrence of adverse reactions was analyzed. Results The ORR and DCR of the study group were higher than those of the reference group, and the differences were statistically significant (P＜0.05). The survival rate of the study group within 1 year after treatment was higher than that of the reference group, and the difference was statistically significant (P＜0.05). The incidence of hypertension in the study group was higher than that in the reference group, and the difference was statistically significant (P＜0.05); there was no significant difference in other adverse reactions between the two groups (P＞0.05). Conclusion During the third line treatment of advanced TNBC patients, the short-term curative effect of Apatinib combined with Capecitabine chemotherapy regimen is considerable, which can improve the survival rate of the patients to a certain extent, and the adverse reactions are in a tolerant state.
京公网安备 11010502046607号